bims-tyki2d Biomed News
on Thymidine kinase 2 deficiency
Issue of 2026–10–04
two papers selected by
Zoya Panahloo, UCB
  1. Current translational perspectives for diagnosis and individualized therapy in rare genetic diseases.
  2. Advances in diagnosis of mitochondrial dysfunction and primary mitochondrial disease.
  1. Commun Med (Lond). 2026 Oct 02. pii: 513. [Epub ahead of print]6(1):
    Current translational perspectives for diagnosis and individualized therapy in rare genetic diseases.
    Sarfaraz K Niazi.
      Rare diseases affect hundreds of millions of individuals worldwide, primarily resulting from genetic factors, with many presenting during childhood. Advances in genome sequencing increasingly enable identification of the responsible gene in more patients; however, only a limited selection of therapies exists to correct or mitigate the underlying genetic defect. This overview delineates the interconnected aspects of diagnosis, evidence generation, treatment, and long-term safety monitoring within an integrated framework. It also posits that the molecular mechanism underlying a disorder, rather than its clinical label, determines both the diagnostic test to be employed and the potential treatment options that may be effective.
    DOI:  https://doi.org/10.1038/s43856-026-01962-3
  2. Dis Model Mech. 2026 Sep 01. pii: dmm052804. [Epub ahead of print]19(9):
    Advances in diagnosis of mitochondrial dysfunction and primary mitochondrial disease.
    Melis Kose, Elizabeth McCormick, James T Peterson, Colleen Muraresku, Angela Viaene, Zarazuela Zolkipli-Cunningham, Marni J Falk.
      Mitochondria are critical cellular organelles engaged in energy production, diverse intermediary metabolic functions and signaling. Inherited genetic disorders directly affecting mitochondrial structure and/or function, known collectively as primary mitochondrial diseases, are among the most complex and heterogeneous inherited conditions, involving dual-genome origin, multisystem manifestations and widely variable clinical severity. These diseases can follow different inheritance patterns and are caused by pathogenic variants in nearly 400 genes encoded by either the mitochondrial or nuclear genome, which commonly impair proteins or RNAs in distinct molecular pathways, resulting in defective energy production by disrupting oxidative phosphorylation. Mitochondrial diseases are challenging to accurately diagnose because of their extensive clinical variability and common features with other metabolic and neuromuscular disorders, as well as limitations in existing diagnostic tools. However, advances in molecular genetics, imaging and systems biology have transformed the diagnostic landscape, enabling more comprehensive and integrative approaches. This Review provides an overview of mitochondrial physiology and outlines the current state of diagnostic strategies, ranging from conventional biochemical assessments and tissue-based analyses to next-generation genome-wide sequencing and the emerging omics technologies. We discuss how combining classical and modern methods can improve diagnostic accuracy and inform clinical decision making. Additionally, we highlight the need for continued refinement of diagnostic frameworks to better support personalized management and future therapeutic development in mitochondrial medicine.
    Keywords:  Mitochondrial diagnostics; Mitochondrial disease biomarkers; Multi-omics; Primary mitochondrial disease; mtDNA sequencing
    DOI:  https://doi.org/10.1242/dmm.052804
This page is being maintained by Thomas Krichel. It was last updated on 2026‒10‒04 at 15:08.